Lumos Diagnostics Holdings Limited (LDX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and welcome to the Lumos Diagnostics first half FY26 results investor briefing. My name is George Copsey-Aftis, and I'll be your moderator for today. The webinar is being recorded today and will be available on Lumos' website. With us today from Lumos Diagnostics, we have the CEO, Doug Ward, and the CFO, Barry Lambert. Good morning to you both. Morning, George. Thank you for being here today. Morning, George. Morning, everyone. The format for today is for Doug and Barry to walk you through the presentation that was released to the ASEC this morning. This should take about 15 to 20 minutes. And then we will be followed by a question and answer session. If you'd like to ask a question, please click on the Q&A tab in the ribbon below and type your question into the box provided. And with that, I'd now like to hand it over to Doug to get us started. Okay, thank you very much, George. Thank you, everyone, for being on today's webinar. I greatly appreciate it. As George said, the presentation was announced today on the ASX, so feel free to pull that off, and you can have that read at your leisure. So with that, Barry, do you mind going to the first presentation slide? Sure. One of the things that we typically always talk about here, even though most of you probably are very familiar with the Lumos story and have followed us for quite some time, is who is Lumos? So I always like to put it in the perspective of Lumos is trying to change the practice of medicine. We are very bullish about what we do, how we do it, and we have the ability to develop our products, manufacture them, and then commercialize and bring those to market. And we do that with a technology that allows us to do it very close to the patient, which that testing is known as point-of-c...